Abstract

Tumor-associated macrophages (TAMs) contribute substantially to the tumor mass of gliomas and have been shown to play a major role in the creation of a tumor microenvironment that promotes tumor progression. Shortcomings of attempts at antiglioma immunotherapy may result from a failure to adequately address these effects. Emerging evidence supports an independent categorization of glioma TAMs as alternatively activated M2-type macrophages, in contrast to classically activated proinflammatory M1-type macrophages. These M2-type macrophages exert glioma-supportive effects through reduced anti-tumor functions, increased expression of immunosuppressive mediators, and nonimmune tumor promotion through expression of trophic and invasion-facilitating substances. Much of our work has demonstrated these features of glioma TAMs, and together with the supporting literature will be reviewed here. Additionally, the dynamics of glioma cell-TAM interaction over the course of tumor development remain poorly understood; our efforts to elucidate glioma cell-TAM dynamics are summarized. Finally, the molecular pathways which underlie M2-type TAM polarization and gene expression similarly require further investigation, and may present the most potent targets for immunotherapeutic intervention. Highlighting recent evidence implicating the transcription factor STAT3 in immunosuppressive tumorigenic glioma TAMs, we advocate for gene array-based approaches to identify yet unappreciated expression regulators and effector molecules important to M2-type glioma TAMs polarization and function within the glioma tumor microenvironment.

Highlights

  • Malignant glioma is uniformly fatal with a median survival of less than 15 months with aggressive treatment [1]

  • This finding is consistent with that of Badie and Schartner who used FACS to demonstrate little to no expression of MHCII, CD80, or CD86 on macrophages freshly isolated from rat gliomas [19]. Expression of these costimulatory molecules on Tumor-associated macrophages (TAMs) could not be restored by stimulation with IFN-γ or LPS [50]. These phenotypic changes on TAMs are likely to be functionally significant in vivo, as we have found that monocytes reisolated following coculture with malignant glioma cells demonstrate an inability to activate allogenic CD4+ T cells [20]

  • Li and Graeber proposed that, whereas glioma-derived TGF-β exerts immunosuppression by driving alternative polarization in TAMs, TGF-β produced by the glioma TAMs may promote tumor growth and invasion by stimulating the upregulation of its own cognate receptors TBRI and TBRII on glioma cells [29] enabling a more potent trophic response to the high concentration of TGF-β proposed to exist in the glioma microenvironment

Read more

Summary

Introduction

Malignant glioma is uniformly fatal with a median survival of less than 15 months with aggressive treatment [1]. Circulating tumor-specific antibodies and cytotoxic T lymphocytes (CTL) have been isolated from the peripheral blood of patients with malignant glioma [12], Journal of Oncology indicating the potential for a competent tumoricidal immune response to glioma within the CNS. This expanding appreciation of intrinsic CNS immune capacity against glioma, coupled with the limited efficacy and profound side effects of current glioma therapies, has prompted a major investigation into immunotherapy as a therapeutic strategy against glioma. Is the glioma-promoting relationship [36] between TAMs and the tumor cells present at tumor initiation, or do glioma cells reeducate classically activated TAMs to express an alternative MDSC phenotype at some point in tumor progression? What intrinsic signaling motifs or master regulators of gene expression underlie immunosuppressive TAM phenotypes under the influence of the complex tumor microenvironment? Do certain convergent effector molecules/pathways within TAMs exert disproportionate effects on immunosuppression or glioma facilitation? In this review we will highlight efforts directed at these questions, as their answers may provide information crucial to the development of effective clinical immunotherapy against malignant gliomas

Origins of Tumor-Associated Macrophages in Glioma
Features of Tumor-Associated Macrophages in Glioma
Dynamics of Glioma-Tam Interaction
Underlying Mechanisms of Alternatively Activated TAMs
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call